Clinical Trials Logo

Clinical Trial Summary

VIDO has developed a vaccine called COVAC-2. The COVAC-2 study vaccine contains a portion of the SARS-CoV-2 spike protein, called S1. The spike protein is the part of the virus that is responsible for attaching to the surface of host cells. COVAC-2 contains a SWE adjuvant. An adjuvant is a compound that is added to a vaccine to help the vaccine produce a better immune response. The SWE adjuvant is similar to another adjuvant, MF59, that is found in influenza vaccines and MF59 containing vaccines have been given to millions of people around the world. The vaccine is expected to stimulate the body to make antibodies against the S1 protein. The antibodies will recognize the viral spike protein if the body is exposed to the virus and prevent severe COVID-19 illness. In animal studies, the immune response generated by the COVAC-2 vaccine was able to protect the vaccinated animals against a severe SARS-CoV-2 infection. This is a Phase 2, placebo-controlled, observer-blind, age-stratified randomized, multicentre study to test the safety and immunogenicity of a dose level of the COVAC-2 vaccine (25 µg protein) administered twice (4 weeks apart) in generally healthy adults 18+ years of age. Up to 300 participants will be enrolled. For an individual participant, the duration of study will be approximately 12 months from the first vaccination (Day 0).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • COVID-19
  • Severe Acute Respiratory Syndrome
  • Severe Acute Respiratory Syndrome Coronavirus 2

NCT number NCT05209009
Study type Interventional
Source University of Saskatchewan
Contact Geofrey Kimbugwe, Dr.
Phone 2560417704191
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date June 2022
Completion date August 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04516811 - Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 Phase 3
Completed NCT04334044 - Treatment of SARS Caused by COVID-19 With Ruxolitinib Phase 1/Phase 2
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Recruiting NCT04466241 - Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial Phase 2/Phase 3
Withdrawn NCT04381923 - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia N/A
Recruiting NCT04402879 - CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals N/A
Recruiting NCT04661631 - Surgery and Lung Ultrasound in COVID-19 Infection
Recruiting NCT04376476 - Host-pathogen Interactions During SARS-CoV-2 Infection N/A
Completed NCT04375098 - Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection Phase 2
Completed NCT04402060 - A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 Phase 1/Phase 2
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT04354779 - Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
Recruiting NCT04367207 - African Covid-19 Critical Care Outcomes Study
Recruiting NCT04409873 - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) Phase 2
Completed NCT04602351 - Communication in ICU During COVID-19
Recruiting NCT04707703 - Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis Phase 3
Active, not recruiting NCT04987528 - Pulmonary Fibrosis During Severe COVID-19 Pneumonia
Completed NCT04667936 - Evaluation of Sedation in COVID-19 ARDS
Completed NCT04423770 - COVID-19 Related Health and Infection Control Practices Among Dentists
Completed NCT04379037 - Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients N/A